When does Botanix (BOT.AX stock) report earnings?

Botanix has an earnings announcement scheduled for **4 March 2026**. Market reaction will likely track cash guidance, R&D progress and any pipeline updates.

What is the current price and short-term outlook for BOT.AX stock?

BOT.AX stock trades at **A$0.056** pre-market on 28 Feb 2026. Meyka AI projects a near-term target of **A$0.09**, but outcomes depend on the upcoming earnings and clinical news.

How does Meyka AI grade BOT.AX stock?

Meyka AI rates BOT.AX with a score out of 100: **64.87 (B)** with a recommendation to **HOLD**. The grade weighs benchmark, sector comparison, growth and key metrics.

What are the main risks for BOT.AX stock after earnings?

Primary risks include negative earnings, disappointing clinical readouts, reduced partner interest, and a volatile share register. Cash runway and guidance will be key for near-term downside.

AU Stocks

A$0.056 pre-market for Botanix Pharmaceuticals (BOT.AX ASX) 28 Feb 2026: Earnings catalysts ahead

ByHuzaifa Zahoor February 27, 2026February 27, 2026

BOT.AX stock opens pre-market at A$0.056 on 28 Feb 2026 ahead of a scheduled earnings update and investor briefing. The stock trades near its 52-week low of A$0.056 with heavy turnover of 19,899,856 shares today. Botanix Pharmaceuticals Limited (BOT.AX, ASX) reports results on 4 March 2026, creating short-term catalysts for price movement. We focus on clinical milestones, cash runway, and earnings metrics. This pre-market piece frames near-term risks and measurable triggers ahead of the result.